CYTOKINETICS, INCORPORATED Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
CYTOKINETICS, INCORPORATED (CYTK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 523.19 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-02-26
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2015-12-31 was -170.66K shares.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2015-09-30 was 13.34K shares, a 134.97% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2015-06-30 was 98.53K shares, a 2665.31% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2015-03-31 was 58.80K shares, a 1493.93% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 523.19K shares, a 10.40% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 473.89K shares, a 3.36% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 458.50K shares, a 10.30% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 415.68K shares, a 40.36% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 523.19K shares 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 473.89K shares 10-K · filed 2026-02-26 | |||
| 2023-12-31 | 458.50K shares 10-K · filed 2026-02-26 | |||
| 2022-12-31 | 415.68K shares 10-K · filed 2025-02-27 | |||
| 2021-12-31 | 296.15K shares 10-K · filed 2024-02-28 | |||
| 2020-12-31 | 234.05K shares 10-K · filed 2023-03-01 | |||
| 2019-12-31 | 353.90K shares 10-K · filed 2021-02-26 | |||
| 2018-12-31 | 884.65K shares 10-K · filed 2019-03-07 | |||
| 2015-12-31 | -170.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | -157.33K shares derived: sum of 2 quarters · filed 2017-03-06 | -58.80K shares derived: sum of 3 quarters · filed 2017-03-06 | 0.00 shares 10-K · filed 2017-03-06 |
| 2015-09-30 | 13.34K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | 111.86K shares derived: sum of 2 quarters · filed 2015-11-05 | 170.66K shares 10-Q · filed 2015-11-05 | |
| 2015-06-30 | 98.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | 157.33K shares 10-Q · filed 2015-08-05 | ||
| 2015-03-31 | 58.80K shares 10-Q · filed 2015-05-04 | |||
| 2014-09-30 | 5.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | 9.24K shares derived: sum of 2 quarters · filed 2014-11-06 | 12.93K shares 10-Q · filed 2014-11-06 | |
| 2014-06-30 | 3.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | 7.25K shares 10-Q · filed 2014-08-07 | ||
| 2014-03-31 | 3.69K shares 10-Q · filed 2014-05-07 | |||
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | 7.93K shares derived: sum of 2 quarters · filed 2013-11-06 | 19.38K shares 10-Q · filed 2013-11-06 | |
| 2013-06-30 | 7.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | 19.38K shares 10-Q · filed 2013-08-07 | ||
| 2013-03-31 | 11.46K shares 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |